ADENOVIRAL HELPER PLASMID

Adeno-associated virus (AAV) technology has quickly become a dominant form of gene therapy for genetic diseases. AA Vs can be produced in large scale in a variety of host cell systems, including mammalian cells, such as HEK293 cells. The present disclosure provides improved adenoviral helper plasmid...

Full description

Saved in:
Bibliographic Details
Main Author DISMUKE, DAVID
Format Patent
LanguageEnglish
French
Published 17.11.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Adeno-associated virus (AAV) technology has quickly become a dominant form of gene therapy for genetic diseases. AA Vs can be produced in large scale in a variety of host cell systems, including mammalian cells, such as HEK293 cells. The present disclosure provides improved adenoviral helper plasmids for the production of recombinant adeno-associated viruses. The present disclosure provides an adenoviral helper plasmid comprising nucleotide sequences encoding E2a, VA RNA, E4; and an L4 region. La présente divulgation concerne des plasmides auxiliaires adénoviraux améliorés pour la production de virus adéno-associés recombinants.
Bibliography:Application Number: CA20223218342